| 2024-04-29 20:29 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.105 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2024-04-29 19:52 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.105 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2024-04-01 09:37 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.11 | News Release200 | Algernon to move forward with DMT stroke research |
| 2024-03-27 12:20 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.09 | Resume Trading385 | Algernon Pharmaceuticals to resume at 9:45 a.m. PT |
| 2024-03-27 12:17 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.12 | News Release200 | Algernon sells ifenprodil research program to Seyltx |
| 2024-03-27 10:24 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.09 | Halt Trading170 | Algernon Pharmaceuticals halted at 7:22 a.m. PT |
| 2024-01-31 10:12 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.08 | News Release200 | Algernon to receive Chinese repirinast patent |
| 2024-01-11 10:22 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.085 | News Release200 | Algernon receives notice of allowance in Japan |
| 2023-12-29 17:56 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.065 | SEDAR MD & A815 | SEDAR MD & A |
| 2023-12-29 17:49 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.065 | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
| 2023-12-27 16:10 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.07 | News Release200 | Algernon closes $280,000 private placement |
| 2023-12-27 10:21 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.07 | News Release200 | Algernon increases private placement to $280,000 |
| 2023-12-12 19:48 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.085 | News Release200 | Algernon arranges $150,000 private placement |
| 2023-11-30 09:50 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.07 | News Release200 | Algernon to receive Chinese patent for Repirinast |
| 2023-11-22 09:17 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.07 | News Release200 | Algernon to sell ifenprodil research program to Seyltx |
| 2023-11-08 10:30 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.075 | News Release200 | Algernon receives Japanese patent for Repirinast |
| 2023-09-06 09:54 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.16 | News Release200 | Algernon receives U.S. patent for repirinast drug |
| 2023-08-08 10:16 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.175 | News Release200 | Algernon subsidiary finalizes phase 2 DMT stroke study |
| 2023-07-28 16:29 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.20 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-07-14 18:12 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.22 | News Release200 | Algernon arranges $205,000 private placement |
| 2023-06-27 09:47 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.19 | News Release200 | Algernon hires Maxim for advisory services |
| 2023-06-05 09:37 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.235 | News Release200 | Algernon doses final cohort in AP-188 phase 1 study |
| 2023-05-31 10:08 | CC:AGN | Algernon Pharmaceuticals Inc (2) | 0.22 | News Release200 | Algernon receives Japanese patent notice of allowance |